Arbutus Biopharma Corp (ABUS) stock
ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 12/3081% below fair value
$4.09+0.06 (+1.49%)
Close on Nov 13, 2026Market cap $809.20MP/E 3.7Yield –
Arbutus Biopharma revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Arbutus Biopharma's revenue for the twelve months ending Sep 30, 2026 was $181.49M, up 1142.6% year over year. For fiscal 2025 it was $14.08M, up 128.2% from the year before. Over ten years it grew -4.9% a year on average. The highest annual figure on record is $39.02M in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.08M | +128.2% |
| FY2024 | Dec 31, 2024 | $6.17M | -66.0% |
| FY2023 | Dec 31, 2023 | $18.14M | -53.5% |
| FY2022 | Dec 31, 2022 | $39.02M | +255.1% |
| FY2021 | Dec 31, 2021 | $10.99M | +58.9% |
| FY2020 | Dec 31, 2020 | $6.91M | +15.0% |
| FY2019 | Dec 31, 2019 | $6.01M | +1.1% |
| FY2018 | Dec 31, 2018 | $5.95M | -44.4% |
| FY2017 | Dec 31, 2017 | $10.70M | +617.6% |
| FY2016 | Dec 31, 2016 | $1.49M | -93.6% |
| FY2015 | Dec 31, 2015 | $23.28M | +55.7% |
| FY2014 | Dec 31, 2014 | $14.95M | -3.3% |
| FY2013 | Dec 31, 2013 | $15.47M | +9.6% |
| FY2012 | Dec 31, 2012 | $14.11M | -16.1% |
| FY2011 | Dec 31, 2011 | $16.81M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $299.00K | -43.5% |
| Q2 FY2026 | Jun 30, 2026 | $1.01M | -90.6% |
| Q1 FY2026 | Mar 31, 2026 | $179.13M | +10054.5% |
| Q4 FY2025 | Dec 31, 2025 | $1.05M | -33.2% |
| Q3 FY2025 | Sep 30, 2025 | $529.00K | -60.5% |
| Q2 FY2025 | Jun 30, 2025 | $10.74M | +522.2% |
| Q1 FY2025 | Mar 31, 2025 | $1.76M | +15.1% |
| Q4 FY2024 | Dec 31, 2024 | $1.57M | -26.6% |
| Q3 FY2024 | Sep 30, 2024 | $1.34M | -71.3% |
| Q2 FY2024 | Jun 30, 2024 | $1.73M | -62.9% |
| Q1 FY2024 | Mar 31, 2024 | $1.53M | -77.1% |
| Q4 FY2023 | Dec 31, 2023 | $2.15M | -65.7% |
| Q3 FY2023 | Sep 30, 2023 | $4.66M | -21.7% |
| Q2 FY2023 | Jun 30, 2023 | $4.65M | -67.3% |
| Q1 FY2023 | Mar 31, 2023 | $6.69M | -46.8% |
| Q4 FY2022 | Dec 31, 2022 | $6.25M | +94.8% |
| Q3 FY2022 | Sep 30, 2022 | $5.95M | +78.2% |
| Q2 FY2022 | Jun 30, 2022 | $14.24M | +511.5% |
| Q1 FY2022 | Mar 31, 2022 | $12.58M | +495.4% |
| Q4 FY2021 | Dec 31, 2021 | $3.21M | +34.4% |
| Q3 FY2021 | Sep 30, 2021 | $3.34M | +119.3% |
| Q2 FY2021 | Jun 30, 2021 | $2.33M | +53.8% |
| Q1 FY2021 | Mar 31, 2021 | $2.11M | +41.7% |
| Q4 FY2020 | Dec 31, 2020 | $2.39M | +47.5% |
| Q3 FY2020 | Sep 30, 2020 | $1.52M | -50.2% |
| Q2 FY2020 | Jun 30, 2020 | $1.51M | +131.9% |
| Q1 FY2020 | Mar 31, 2020 | $1.49M | +119.6% |
| Q4 FY2019 | Dec 31, 2019 | $1.62M | -3.6% |
| Q3 FY2019 | Sep 30, 2019 | $3.06M | +92.9% |
| Q2 FY2019 | Jun 30, 2019 | $653.00K | -47.5% |
| Q1 FY2019 | Mar 31, 2019 | $679.00K | -52.7% |
| Q4 FY2018 | Dec 31, 2018 | $1.68M | -33.8% |
| Q3 FY2018 | Sep 30, 2018 | $1.59M | -77.0% |
| Q2 FY2018 | Jun 30, 2018 | $1.24M | +19.7% |
| Q1 FY2018 | Mar 31, 2018 | $1.44M | +511.1% |
| Q4 FY2017 | Dec 31, 2017 | $2.53M | – |
| Q3 FY2017 | Sep 30, 2017 | $6.89M | – |
| Q2 FY2017 | Jun 30, 2017 | $1.04M | – |
| Q1 FY2017 | Mar 31, 2017 | $235.00K | – |
| Q4 FY2016 | Dec 31, 2016 | -$195.00K | – |
See a number that looks wrong?